Anales de la RANM

253 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 NUEVOS FÁRMACOS DONADORES DE ÓXIDO NÍTRICO Berrazueta Fernández JR An RANM. 2025;142(03): 246 - 254 DECLARACIÓN DE TRANSPARENCIA El autor/a de este artículo declara no tener ningún tipo de conflicto de intereses respecto a lo expuesto en el presente trabajo. BIBLIOGRAFÍA 1. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988; 333(6174):664-6. doi: 10.1038/333664a0. PMID: 3131684. 2. Moncada S, Palmer RM, Higgs EA. Biosynthe- sis of nitric oxide from L-arginine. A pathway for the regulation of cell function and commu- nication. Biochem Pharmacol. 1989;38:1709- 15. doi: 10.1016/0006-2952(89)90403-6. PMID: 2567594. 3. Feehlisch M, Noack EA. Correlation between nitnc oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987;139:19-30 4. Feelisch,M, Ostrowski, J. and Noack, E.. On the mechanism of NO release from sydno- nimines. Journal of Cardiovascular Phar- macology, 1989; 14, supplement 11, S13- S22. (PMID:2484692 5. Berrazueta JR, López Jaramillo P, Moncada S. El óxido nítrico: de vasodilatador endogeno a mediador biologico. Rev Esp Cardiol 1990; 43: 421-431, 6. Berrazueta JR, Ochoteco J, Poveda JJ, Ruiz B, Olalla JJ, Gutiérrez Escalada B, Salas E. Tra- tamiento transcutáneo de la tromboflebitis superficial con el donador exógeno de óxi- do nítrico: Nitroglicerina. Rev Esp Cardiol 1991;44:424-426, 7. Berrazueta JR, Poveda JJ, Ochoteco J, Amado JA, Puebla F, Salas E, Sarabia M. The anti-in- flammatory and analgesic action of transder- mal glyceryltrinitrate in the treatment of infu- sion-related thrombophlebitis. Postgrad Med J. 1993;69:37-40. doi: 10.1136/pgmj.69.807.37. PMID: 8383319; PMCID: PMC2399598 8. Berrazueta JR, Fleitas M, Salas E, Amado JA, Poveda JJ, Ochoteco A, Sánchez de Vega MJ, Ruiz de Celis G. Local transdermal glyceryl trinitrate has an antiinflammatory action on thrombophlebitis induced by sclerosis of leg varicose veins. Angiology. 1994;45:347-51. doi: 10.1177/000331979404500503. PMID: 8172381 9. Berrazueta JR, Salas E, Ochoteco A, Poveda JJ, Sánchez de Vega MJ. Acción analgésica peri- férica del donador de óxido nítrico: Nitrogli- cerina. Estudio control frente a placebo de la acción de la Nitroglicerina transdérmica sobre la sensibilidad dolorosa del antebrazo. Rev Esp Cardiol. 1993; 46:10-14. 10. Hodosan, F.; Mantsch, O.; Jude, I.; Breazu, D.; Cuparencu, B.;Sterescu, N. Nitrate esters of steroid hormones and related compounds: pre- paration and biological properties. Arzneim.- Forsch. 1969; 19:684–685. 11. Burgaud, J. L.; Ongini, E.; Del Soldato, P. Ni- tric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann. N. Y. Acad. Sci.2002; 962:360–371. 12. Wallace, J. L.; del Soldato, P. The therapeutic po- tential of NONSAIDS. Fundam. Clin. Pharma- col.2003; 17:11– 20. 13. Herman, A. G. & Moncada, S. Therapeutic poten- tial of nitric oxide donors in the prevention and treatment of atherosclerosis.Eur Heart J 2005; 26: 1945–1955, doi: 10.1093/eurheartj/ehi333. 14. Bonini, M. G. et al. Constitutive nitric oxi- de synthase activation is a significant route for nitroglycerin-mediated vasodilation. Proc Natl Acad Sci USA. 2008; 105, 8569–8574, doi: 10.1073/pnas.0708615105. 15. Mao, M. et al. Nitroglycerin drives endothelial nitric oxide synthase activation via the phospha- tidylinositol 3-kinase/protein kinase B pathway. Free Radic Biol Med 2012; 52: 427–435, doi: 10.1016/j.freeradbiomed.2011.09.020. 16. Sydow, K. et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross- tolerance. J Clin Invest 2004; 113, 482–489, doi: 10.1172/JCI19267. 17. Ardekani, S., Scott, H., Gupta, S. et al. Nanolipo- somal Nitroglycerin Exerts Potent Anti-Inflam- matory Effects. Sci 2015; Rep 5, 16258. https:// doi.org/10.1038/srep16258. 18. Keefer,LK. Nitric Oxide (NO)- and Nitroxyl (HNO)-Generating Diazeniumdiolates (NO- NOates): Emerging Commercial Opportu- nities. Current Topics in Medicinal Chemis- try, 2005; 5: 625-636(12) DOI: https://doi. org/10.2174/1568026054679380 19. Tanveer A. Tabish; Mark J. Crabtree; Helen E. Townley; Paul G. Winyard; Craig A. Lygate. Nitric Oxide Releasing Nanomaterials for Cardiovascular Applications. JACC: Basic to Translational Science 2024;9:691–709. DOI:10.1016/j.jacbts.2023.07.017 20. Molloy J, Martin JF, Baskerville PA, Fraser SC, Markus HS . S-nitrosoglutathione reduces the rate of embolization in humans. Circulation 1998; 98: 1372–1375. 21. Seabra AB, Fitzpatrick A, Paul J, De Oliveira MG, Weller R . Topically applied S-nitrosothiol- containing hydrogels as experimental and phar- macological nitric oxide donors in human skin. Br J Dermatol 2004;151: 977–983 22. Megson IL. Lipophilic S-nitrosothiols: a means of tar- geted delivery of nitric oxide to areas of endothelial injury? Drugs of the Future 2002; 27: 777–781. 23. J Du, M Yu, W Tuo, S Zhang, Y Sun; Anthra- cene and pyrene containing fluorescent me- tallacycles/cages (MOCs) and their applica- tions. APL Mater. 1 May 2025; 13 (5): 050601. https://doi.org/10.1063/5.0266382 24. Kashfi K, Rigas B. Molecular targets of nitric- oxide-donating aspirin in cancer. Biochem Soc Trans 2005; 33: 701–704. 25. Uchida Y, Nakamura M, Shimizu S, Shirasawa Y, Fujii M. Vasoactive and beta-adrenoceptor bloc- king properties of 3, 4- dihydro-8-(2-hydroxy- 3-isopropylamino) propoxy-3-nitroxy-2H- 1-ben- zopyran (K-351), a new antihypertensive agent. Arch Int Pharmacodyn Ther 1983; 262: 132–149.